FCGR2A and acute myeloid leukemia: Nor could we detect any capacity of daratumumab to induce antibody-dependent cellular cytotoxicity (ADCC) by FcγR-bearing effector cells at different drug concentrations in AML (Fig. 3d and Supplementary Fig. S3e).